Role of Forkhead box F1 in the Pathobiology of Pulmonary Arterial Hypertension
Jose G. Gomez‐ArroyoiD, Arjan C. HouwelingiD, Harm Jan BogaardiD, Jurjan AmaniD, Joseph KitzmilleriD, Aleksey PorolloiD, Dennis DooijesiD, Lilian J. MeijboomiD, Phillip Hale, Michael W. PauciuloiD, Jason S. HongiD, Na ZhuiD, Carrie L. WelchiD, Yufeng SheniD, William J. ZachariasiD, Francis X. McCormackiD, Micheala A. AldrediD, Matthew T. WeirauchiD, Stefan GräfiD, Christopher RhodesiD, Wendy K. ChungiD, Jeffrey A. WhitsettiD, Lisa Joy MartiniD, Vladimir V. KalinichenkoiD, William C. NicholsiD
Abstract
RationaleApproximately 80% of patients with non-familial pulmonary arterial hypertension (PAH) lack identifiable pathogenic genetic variants. While most genetic studies of PAH have focused on predicted loss-of-function variants, recent approaches have identified ultra-rare missense variants associated with the disease. FOXF1 encodes a highly conserved transcription factor, essential for angiogenesis and vasculogenesis in human and mouse lungs. ObjectivesWe identified a rare FOXF1 missense coding variant in two unrelated probands with PAH. FOXF1 is an evolutionarily conserved transcription factor required for lung vascular development and vascular integrity. Our aims were to determine the frequency of FOXF1 variants in larger PAH cohorts compared to the general population, study FOXF1 expression in explanted lung tissue from PAH patients versus control (failed-donor) lungs, and define potential downstream targets linked to PAH development. MethodsThree independent, international, multicenter cohorts were analyzed to evaluate the frequency of FOXF1 rare variants. Various composite prediction models assessed the deleteriousness of individual variants. Bulk RNA sequencing datasets from human explanted lung tissues were compared to failed-donor controls to determine FOXF1 expression. Bioinformatic tools identified putative FOXF1 binding targets, which were orthogonally validated using mouse ChIP-seq datasets. Measurements and Main ResultsSeven novel or ultra-rare missense coding variants were identified across three patient cohorts in different regions of the FOXF1 gene, including the DNA binding domain. FOXF1 expression was dysregulated in PAH lungs, correlating with disease severity. Histological analysis showed heterogeneous FOXF1 expression, with the lowest levels in phenotypically abnormal endothelial cells within complex vascular lesions in PAH samples. A hybrid bioinformatic approach identified FOXF1 downstream targets potentially involved in PAH pathogenesis, including BMPR2. ConclusionsLarge genomic and transcriptomic datasets suggest that decreased FOXF1 expression or predicted dysfunction is associated with PAH.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 4
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Rare variant analysis of 4,241 pulmonary arterial hypertension cases from an international consortium implicate FBLN2, PDGFD and rare de novo variants in PAH
Na Zhu, Emilia M. Swietlik, … National Cohort Study of Idiopathic and Heritable PAH·Genome MedicinePeer-reviewed·May 10, 2021
- Identification of novel rare sequence variation underlying heritable pulmonary arterial hypertension
Stefan Gräf, Matthias Haimel, … Nicholas W. Morrell·Nature CommunicationsPeer-reviewed·Apr 11, 2018
- E2F1 Mediates SOX17 Deficiency-Induced Pulmonary Hypertension
- Novel risk genes and mechanisms implicated by exome sequencing of 2,572 individuals with pulmonary arterial hypertension
Na Zhu, Michael W. Pauciulo, … William C. Nichols·Genome MedicinePeer-reviewed·Nov 14, 2019
- Genetic determinants of risk and survival in pulmonary arterial hypertension
Christopher J. Rhodes, Ken Batai, … Quinten Waisfisz·The Lancet Respiratory MedicinePeer-reviewed·Dec 5, 2018
- Identification of drug candidates for rescue of SOX17 gene targets in pulmonary arterial hypertension
Eleni Vasilaki, Bedia Akosman, … Christopher J. Rhodes·bioRxiv·May 21, 2026